LENZ Therapeutics, Inc. (LENZ) Stock Grade

About LENZ Therapeutics, Inc.'s fundamentals

LENZ Therapeutics is a biotechnology company with a market capitalization of $124.2 million that is not yet profitable, reporting a net loss in its latest annual statement with a net margin of -430.3%. The company generated no year-over-year revenue growth, indicating it is in early development stages without meaningful commercial sales. As a pre-revenue or early-stage biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay dividends.